ArticleHepatology communications2026
Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSemi-annual abdominal ultrasound plus alpha-fetoprotein (AFP) is recommended for HCC surveillance but has limited performance, particularly in patients with metabolic dysfunction-associated steatotic liver disease. We aimed to validate a blood-based test combining cell-free DNA methylation profiling with AFP to improve HCC detection in at-risk individuals.
methodsBetween September 1, 2023, and April 30, 2025, 135 patients with HCC and 167 at risk for HCC were prospectively recruited at 2o medical centers; archived samples (46 HCC and 32 at-risk) were also included. A cell-free DNA methylation assay was performed to generate methylation scores, and AFP testing was conducted as part of standard of care. A pretrained model integrated methylation scores and AFP levels for HCC detection.
resultsThe combination of methylation and AFP tests achieved an AUC of 0.94 (95% CI, 0.92-0.96) for detecting HCC in at-risk individuals, significantly outperforming both methylation alone (AUC: 0.92, 95% CI, 0.89-0.95; p=0.001) and AFP alone (AUC: 0.83, 95% CI, 0.79-0.87; p<0.0001). In patients with early-stage HCC (within Milan Criteria), the combined test achieved an AUC of 0.90 (95% CI, 0.86-0.94), outperforming methylation alone (AUC: 0.88, 95% CI, 0.83-0.92; p=0.002) and AFP alone (AUC: 0.81, 95% CI, 0.76-0.86; p<0.0001). At 92.0% specificity, sensitivity for early-stage HCC was 73% (95% CI, 64%-80%) with the combined test, compared with 62% (95% CI, 52%-71%; p=0.025) for methylation alone and 52% (95% CI, 43%-62%; p<0.0001) for AFP alone. Sensitivity improvements were consistent across major demographic and etiologic subgroups.
conclusionsThe combination of cell-free DNA methylation with AFP shows promising performance for early-stage HCC detection in this case-control validation study and warrants further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.